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Nitroalkene derivatives of nitro-oleic acid (OA-NO2) are endogenous lipid products with novel signaling properties, particularly
the activation of PPARs. The goal of this proposal was to examine the therapeutic potential of this OA-NO2 in treatment of
obesity and obesity-related conditions in obese Zucker rats. The animals were randomly divided to receive OA-NO2, oleic acid
(OA), both at 7.5μg/kg/d, or vehicle ethanol via osmotic mini-pumps for 2 weeks. Following OA-NO2 treatment, food intake
was decreased as early as the ﬁrst day and this eﬀect appeared to persist throughout the experimental period. At day 14, body
weight gain was signiﬁcantly reduced by OA-NO2 treatment. This treatment signiﬁcantly reduced plasma triglyceride and almost
normalizedplasmafreefattyacidandsigniﬁcantlyincreasedplasmahigh-densitylipid(HDL).TheplasmaTBARSandproteinuria
were paralelly decreased. In contrast, none of these parameters were aﬀected by OA treatment. After 14 days of OA-NO2 treatment,
hematocrit,asurrogateofﬂuidretentionassociatedwithPPARγ agonists,remainedunchanged.Together,thesedatademonstrated
that OA-NO2 may oﬀer an eﬀective and safe therapeutic intervention for obesity and obesity-related conditions.
1.Introduction
The prevalence of overweight and obesity has dramatically
increased during the past two decades. According to results
of recent National Health and Nutrition Examination Survey
(NHANES), 66.3% of adults in the United States are
overweight or obese deﬁned as a body mass index (BMI)
of 25 or greater. Of these, 32.2% are obese deﬁned as a
BMI of 30 or greater [1]. The World Health Organization
has estimated that worldwide, over one billion adults
are overweight, with at least 300 million of them being
obese [2]. Obesity is associated with a variety of chronic
diseases, including endocrine disorders including metabolic
syndrome, type 2 diabetes, and dislipidemia; cardiovascular
disease including hypertension, congestive cardiomyopathy,
stroke, and coronary heart disease; respiratory disorders
including dyspnea and obstructive sleep apnea; depression,
sleep disorders, musculoskeletal disorders, and gallblad-
der disease. Life style modiﬁcation including exercise and
calorie restriction remains the cornerstone of anti-obesity
therapy but the long term success rate is low. In recent
years, pharmacotherapy of obesity has received much atten-
tion.
Recently, nitrated free fatty acids (NO2-FA), notably
nitroalkene derivatives of linoleic acid (nitrolinoleic acid,
LNO2)andoleicacid(O A -NO 2)ar ef oundt obee nd og e nous
molecules with several attractive signaling properties [3,
4]. In particular, nitroalkenes are found to be a robust
endogenous ligand for peroxisome proliferator-activated
receptor γ (PPARγ)andtheyalsoactivatePPARαandPPARδ
at increasing concentrations [3, 4] .P P A R sh a v ee m e r g e da sa
noveltherapeutictargetfortreatmentofvariouscomponents
of metabolic syndrome. For example, synthetic PPARγ
agonists,thiazolidinediones,havebeenwidelyusedasinsulin
sensitizing agents for treatment of type 2 diabetes; synthetic
PPARα agonists such as cloﬁbrate and fenoﬁbrate have been
used in clinics for more than 30 years as lipid lowering
agents [5–8]. Unfortunately, these synthetic agents are often
associated with various toxicities [7, 9–11]. The goal of the
present study was to examine the therapeutic potential of
OA-NO2 in an experimental model of obesity and metabolic
syndrome.2 PPAR Research
2.MaterialsandMethods
2.1. Animals. Four month-old male obese Zucker and lean
rats were purchased from Charles River Laboratory (Wilm-
ington, MA). All animals were housed at the University
of Utah Comparative Medicine Center, maintained on a
12-hour light/dark cycle, and provided food and water ad
libitum. Procedures and protocols followed guidelines set by
the Laboratory Animal Care Committee at the University of
Utah.
2.2. Materials. 9-Nitrooleic acid and 10-nitrooleic acid are
two regioisomers of nitrooleic acid (OA-NO2). These regioi-
somersareformedbynitrationofoleicacidinapproximately
equal proportions as described elsewhere [4]. The two
compounds were purchased from Cayman Chemicals (Ann
Arbor, MI) (9-nitrooleic acid: Cat#10008042; 10-nitrooleic
acid:Cat#10008043)andusedasa1:1mixtureoftheisomers.
2.3. Protocols for Animal Experiments. Under general anes-
thesia, obese Zucker rats were subcutaneously implanted
with a mini-pump (DURECT Corporation, Cupertino, CA)
delivering OA-NO2, oleic acid (OA), both at 7.5μg/kg/d, or
vehicle ethanol for 2 weeks. Age and gender matched lean
ratswithvehicletreatmentwereusedascontrols.Foodintake
was determined periodically; body weight and collections of
blood and 24-h urine samples were determined at the end of
the experiments. Animals were fasted from 6:00 pm to 9:00
am before blood sampling. Blood sampling was conducted
by making a small cut (∼2mm) in the tail using razor blade.
24-hour urine was collected using metabolic cages.
2.4. Plasma Glucose and Lipids. The following determina-
tions were analyzed by using ROCHE, Modular P in the Uni-
versity Hospital Chemistry Laboratory: glucose, cholesterol,
triglyceride, HDL, and LDL; non-esterided fatty acids were
determined by using a colorimetric method (Cat# SFA-5,
ZenBio, Research Triangle Park, NC).
2.5. Hematocrit. Hematocrit was determined as the popular
ways. Brieﬂy, 5–10μl of blood was collected from tail cut
using a 10μl capillary glass (Idaho Technology). One side of
the tube was sealed with Hemato-Seal and then centrifuged
for 4 minutes in a Thermo IEC microcentrifuge machine.
The total height of sample and height of the red blood cell
column were measured. The hematocrit reﬂects the ratio
between the red blood cell column and total height.
2.6. Measurement of Thiobarbituric Acid-Reactive Substances
(TBARS). The measurement of TBARS was based on the
formation of malondialdehyde (MDA) by using a commer-
cially available TBARS Assay kit (Cat#: 10009055, Cayman
Chemical, Ann Arbor, MI).
2.7. Total Urine Protein. 24-h urinary protein excretion was
measured by using Commassie blue.
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Figure 1: Food intake in male 4-mo-old obese Zucker rats (obese)
over 14 days of infusion with vehicle, OA-NO2, or OA, each at
7.5μg/kg/d via osmotic mini-pumps. Age and gender matched lean
rats with vehicle treatment were used as controls. Lean: n = 3;
Vehicle: n = 7; OA-NO2: n = 5; OA: n = 5. ∗, P<. 01 versus
Obese/Vehicle; #, P<. 05 versus OA during the corresponding
period. Data are mean ± SE.
2.8. Statistical Analyses. All data are presented as means ±
SEM. Diﬀerences between groups were analyzed by unpaired
t test or 2-way ANOVA, followed by Bonferroni post hoc
test using GraphPad Prism software version 3.03 (GraphPad
Software, San Diego, CA). Diﬀerences within groups, before
and after OA-NO2 treatment, were analyzed by paired t test.
Ap r o b a b i l i t yv a l u eo f<0.05 was considered signiﬁcant.
3. Results
3.1. Eﬀect of OA-NO2 on Food Intake and Body Weight Gain.
Starting from 4 months of age, the obese Zucker rats were
chronically infused for 2 weeks with vehicle, OA-NO2 or OA
each at 7.5μg/kg/day via an osmotic mini-pump. Untreated
age-matched lean rats were used as controls. As shown in
Figure 1,O A - N O 2 treatment in obese Zucker rats reduced
food intake as early as day 1 (Vehicle 36.6 ± 1.01 versus
OA-NO2 31.2 ± 1.04g, P<. 01), and this eﬀect appeared
to persist throughout the experiment except that only a
trend was detected on day 14. Over the 14-day period, obese
Zucker rats exhibited a signiﬁcant increase in body weight
as compared with lean controls (obese Zucker 48.0 ± 4.0
versus lean 16.7 ± 1.2g, P< . 01). The body weight gain
in obese Zucker rats was reduced to 34.0 ± 1.1g by OA-NO2
treatment (P<. 05). In contrast, a 14-day treatment with OA
in obese Zucker rats at the same dose and same infusion rate
did not aﬀect food intake or body weight.
3.2.EﬀectofOA-NO2 onBiochemicalParameters. Atbaseline,
obese Zucker rats already developed signiﬁcant hypertriglyc-
eridemiaascomparedwithleancontrols(549.1 ±63.4versus
78.0 ± 11.2mg/dl, P<. 01) and the values continued to
rise on day 14. The baseline values of plasma triglyceride in
the OA-NO2 a n dO Ag r o u p s( O A - N O 2: 556.8 ± 45.8mg/dl;PPAR Research 3
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Figure 2: Body weight gain in obese Zucker rats before and after
14-d infusion with vehicle, OA-NO2, or OA. Lean rats with vehicle
treatment were used as controls. Lean: n = 3; Vehicle: n = 7; OA-
NO2: n = 5; OA: n = 5. Data are mean ± SE.
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Figure 3: Plasma triglyceride in obese Zucker rats before and after
14-d infusion with vehicle, OA-NO2, or OA. Lean rats with vehicle
treatment were used as controls. Lean: n = 3; Vehicle: n = 7; OA-
NO2: n = 5; OA: n = 5. Data are mean ± SE.
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Figure 4: Plasma cholesterol in obese Zucker rats before and after
14-d infusion with vehicle, OA-NO2, or OA. Lean rats with vehicle
treatment were used as controls. Lean: n = 3; Vehicle: n = 7; OA-
NO2: n = 5; OA: n = 5. Data are mean ± SE.
OA: 637.0 ± 102.0mg/dl) were comparable to the vehicle
group. At day 14, the values in OA-NO2 group (423.0
± 46.0mg/dl) but not OA group (687.0 ± 99.0mg/dl)
was signiﬁcantly lower than the vehicle control (877.4 ±
64.9mg/dl). Plasma non-esteried free fatty acids followed
a similar pattern as plasma triglyceride. Of particular note,
a 14-day treatment with OA-NO2 but not OA decreased
plasma non-esteried free fatty acid concentrations to a value
almost comparable to the lean control. In contrast, plasma
cholesterol was unaﬀected by OA-NO2 or OA. Interestingly,
a 14-day OA-NO2 treatment elevated plasma HDL from 26.8
± 1.49 to 32.6 ± 2.6mg/dl (P<. 05), paralleled by the
increased HDL to total cholesterol ratio. In contrast, both
plasma HDL and the HDL to cholesterol ratio remained
unchanged after 14-day treatment with vehicle and OA.
At day 14, obese Zucker rats exhibited normal glycemia
(93.7 ± 6.9 versus mg/dl) that was not aﬀected by OA-
NO2 treatment (85.6 ± 5.3mg/dl, P>. 05). Plasma
aspartate aminotransferase (AST)/alanine aminotransferase
(ALT) and BUN were evaluated to reﬂect liver and kidney
function,respectively;noneoftheseparameterswereaﬀected
by OA-NO2 treatment (AST: 156.8 ± 18.4 versus 159 ±
7.7U/L, P>. 05; ALT: 135.0 ± 18.9 versus 104.5 ± 3.9U/L,
P>. 05; BUN: 15.0 ± 1.1 versus 15.8 ± 0.7mg/dl, n = 4-
5, P>. 05). Therefore, these data do not indicate obvious
hepatic or renal toxicities associated with OA-NO2.
3.3. Eﬀects of OA-NO2 on Oxidative Stress, Proteinuria, and
Hematocrit. Plasma TBARS was assessed as a measure of
oxidative stress in obese Zucker rats. The obese rats had a
marked increase in plasma TBARS as compared with lean
controls (14.83 ± 1.47 versus 1.97 ± 0.63μM, P<. 01). A
14-dayOA-NO2 treatmentdecreasedplasmaTBARSlevelsto
8.26±2.31μM(P<. 01versusthebaselineinthesamegroup
or the vehicle group at the corresponding time period).
As compared with the lean control (12.22 ± 0.73mg/24
hours), obese Zucker rats exhibited progressive proteinuria
(day 0: 34.88 ± 8.17; day 14: 78.5 ± 19.7mg/24 hours). OA
treatment tended to exhibit an anti-proteuric eﬀect but this
did not reach a statistical signiﬁcance.
PPARγ agonists are limited by signiﬁcant ﬂuid retention
as reﬂected by body weight gain and plasma volume expan-
sion. The drop of hematocrit has been used as a surrogate
marker of plasma volume expansion since these com-
pounds do not inﬂuence erythropoiesis. Therefore we exam-
ined hematocrit in awake animals; hematocrit remained
u n c h a n g e di r r e s p e c t i v eo fO A - N O 2 or OA treatment.
4. Discussion
linoleic acid (nitrolinoleic acid, LNO2)a n do l e i ca c i d
(OA-NO2) are two major nitroalkene derivatives formed
endogenously via NO-dependent oxidative reactions [12,
13]. Studies in cell cultures have demonstrated PPAR ligand
activities of these derivatives [3, 4]. In this regard, LNO2 was
initially reported to be a potent an endogenous ligand for
PPARγ that acts within physiological concentration ranges
[3]. Subsequently, OA-NO2 was shown to be a more robust4 PPAR Research
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Figure 5: Plasma HDL (a) and the ratio of HDL to total cholesterol
(b) before and after 14-d infusion with vehicle, OA-NO2,o rO A .
Lean rats with vehicle treatment were used as controls. Lean: n = 3;
Vehicle: n = 7; OA-NO2: n = 5; OA: n = 5. Data are mean ± SE.
PPARγactivatorascomparedwithLNO2 anditalsoactivated
PPARα and PPARδ at increasing concentrations [3, 4].
The three subtypes of PPARs are critically important for
the control of glucose homeostasis and lipid metabolism.
Therefore we were prompted to evaluate the therapeutic
potential of nitroalkene derivatives in an animal model of
obesity and metabolic syndrome. Here we demonstrate that
a 14-day osmotic delivery of a low dose (7.5μg/kg/d) of
OA-NO2 in obese Zucker rats produced beneﬁcial eﬀects
on various components of metabolic syndrome, including
obesity, hyperlipidemia, and proteinuria, accompanied by an
immediate reduction of food intake.
Epidemiological studies demonstrate that ingestion of
polyunsaturated fatty acids (PUFA) and monounsaturated
fatty acids (MUFA) but ingestion of saturated fatty acid
deteriorates insulin resistance and obesity-related diseases
[14]. An issue arises as to whether the beneﬁcial eﬀects
of OA-NO2 observed in obese Zucker rats are attributable
to the native OA. This possibility is not supported by
a previous study showing that chronic administration of
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Figure 6: Plasma non-esteried fatty acids in obese Zucker rats
before and after 14-d infusion with vehicle, OA-NO2, or OA. Lean
rats with vehicle treatment were used as controls. Lean: n = 3;
Vehicle: n = 7; OA-NO2: n = 5; OA: n = 5. Data are mean ± SE.
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Figure 7: Plasma TBARS in obese Zucker rats before and after 14-
d infusion with vehicle, OA-NO2, or OA. Lean rats with vehicle
treatment were used as controls. Lean: n = 3; Vehicle: n = 7; OA-
NO2: n = 5; OA: n = 5. Data are mean ± SE.
dietary oleic acid in obese Zucker at a dose roughly
500 times higher than that in the present study fails to
aﬀect body weight, plasma glucose and lipids despite the
amelioration of pancreatic islet disruption [15]. Along this
line, the beneﬁts of omega-3 polyunsaturated fatty acid
(LC omega-3 PUFA) are also seen with a substantially high
dose [16]. More importantly, we found that administration
of OA at the same dose and with the same route did
not produce any measurable eﬀects on body weight or
other metabolic parameters. It appears evident that the
beneﬁcial eﬀects of OA-NO2 observed in obese Zucker rats
are derived from the nitration of OA but not the native fatty
acid.PPAR Research 5
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Figure 8: Proteinuria in obese Zucker rats before and after 14-
d infusion with vehicle, OA-NO2, or OA. Lean rats with vehicle
treatment were used as controls. Lean: n = 3; Vehicle: n = 7; OA-
NO2: n = 5; OA: n = 5. Data are mean ± SE.
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Figure 9: Hematocrit in obese Zucker rats before and after 14-
d infusion with vehicle, OA-NO2, or OA. Lean rats with vehicle
treatment were used as controls. Lean: n = 3; Vehicle: n = 7; OA-
NO2: n = 5; OA: n = 5. Data are mean ± SE.
The mechanism of action of OA-NO2 in obese Zucker
rats remains elusive but the involvement of PPARs appears
conceivable. PPARα agonists (Wy-14643 and GW7647)
and endogenous PPARα agonists (oleylethanolamide;OEA)
treatment induces satiety and reduces body weight gain [17–
20], an eﬀect almost analogous to that of OA-NO2 in obese
Zucker rats. The rapid onset of appetite-suppressing eﬀect
(within a day) between PPARα agonists and OA-NO2 is also
similar. Furthermore, PPARα agonists are well known to
reduce plasma triglyceride and increase HDL, a proﬁle again
similar to that of OA-NO2. Together, PPARα activity appears
to explain most of metabolic eﬀects of OA-NO2 in obese
Zucker rats. Of note, both OEA and OA-NO2 are naturally
occurring products derived from the same precursor, OA,
and exert a similar role in regulation of satiety and body
weight. It is an intriguing possibility that the two derivatives
of OA converge on a common ﬁnal pathway involving
PPARα.H o w e v e r ,t h ed i ﬀerences may exist in regulation of
their production. OEA is produced by the small intestine in
response to food intake [17, 20] while the production of OA-
NO2 appears to be primarily regulated by NO-dependent
oxidative reactions which may or may not be related to
feeding.
Although OA-NO2 is a robust PPARγ a c t i v a t o ri na ni n
vitrosystem,theinvolvementofPPARγ inOA-NO2 signaling
in the current experimental model might be minimal. In
a sharp contrast to the appetite-suppressing and weight-
lowering eﬀects of OA-NO2, the synthetic PPARγ agonists,
thiazolidinediones, cause increases in food intake [21, 22]
and body weight and plasma volume expansion [10, 23, 24].
The lack of an eﬀect of the PPARδ/β agonist on food intake
[17] also does not support involvement of PPARδ in the
a n o r e c t i ca c t i o no fO A - N O 2. However, it is still possible
that these two PPAR subtypes may partially contribute to
some aspects of OA-NO2 action, such as the lipid-lowering
and proteinuria-lowering eﬀects. Indeed, all three PPAR
subtypes share common lipid-lowering properties [25–28],
and PPARα [29–32]a n dP P A R γ [33–36] exert similar
renoprotective eﬀects in animals or humans with diabetic
nephropathy. It should be pointed out that in addition to
PPARs, nitrated lipids can engage other pathways such as
NO, NF-kB, and hemoxygnease-1. Whether these PPAR-
independent or other as yet unidentiﬁed pathways play a
contributory role in mediating the metabolic actions of OA-
NO2 remains unclear.
Whatever the underlying mechanism, our data suggest
that OA-NO2 may oﬀer therapeutic opportunities for man-
agement of obesity and obesity-related conditions. At the
present, most of the anti-obesity agents target neurotrans-
mitter receptors and are often associated with increased
risk of psychiatric events. One example is rimonabant, a
selective antagonist of the cannabinoid type 1 receptor,
which is the most oﬃcious weight-lowering agent but causes
depression and anxiety [37–39]. Because of the psychiatric
side eﬀects, the Committee for Medicinal Products for
Human Use of the European Medicines Agency (EMEA)
has recommended suspension of rimonabant as an anti-
obesity therapy [40]. OA-NO2 is unique in that it is a
naturally occurring product likely acting nuclear receptors,
thus representing a novel class of weight-lowering agents.
We demonstrated that it is not only highly eﬀective but
also well tolerated. Moreover, OA-NO2 exhibited beneﬁcial
eﬀects beyond weight loss. For example, it improved lipid
proﬁle, suppressed oxidative stress, and reduced protein-
uria.
In summary, the present study describes novel thera-
peutic potential of OA-NO2 in a rodent model of obesity
and metabolic syndrome. A low-dose treatment produces
anorexia and reduces body weight gain, accompanied by
improved lipid proﬁle, and reduction of oxidative stress and
proteinuria, in the absence of plasma volume expansion.
These eﬀects are derived from the nitration of OA rather
than the native fatty acid. As a natural product, OA-NO2
appears to be an optimal pharmacotherapy for obesity and
obesity-related conditions with a superior eﬃcacy and safety
proﬁle.6 PPAR Research
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